on DocMorris AG (isin : CH0042615283)
DocMorris Accelerates Prescription Medicine Growth
In the third quarter of 2024, DocMorris AG reported a 12.2% increase in prescription medicine revenue in Germany, with a notable acceleration to over 25% in recent weeks. This growth is attributed to the rising trend of e-prescriptions, counterbalancing the decline in paper prescriptions. The company saw a 1.9% increase in over-the-counter (OTC) medicine sales, and TeleClinic doubled its revenue from last year.
Pablo Ros Gomez will assume the role of Chief Technology Officer, succeeding Madhu Nutakki. Furthermore, the company will close the Zur Rose Pharma logistics site in Germany by year-end, relocating operations to Heerlen.
DocMorris forecasts a revenue increase of 5-10% for 2024, alongside continued strategic investments and cost management efforts.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DocMorris AG news